Health-Chem Corporation
Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts researc… Read more
Health-Chem Corporation (HCLC) - Net Assets
Latest net assets as of June 2007: $-16.43 Million USD
Based on the latest financial reports, Health-Chem Corporation (HCLC) has net assets worth $-16.43 Million USD as of June 2007.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.54 Million) and total liabilities ($21.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-16.43 Million |
| % of Total Assets | -296.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -525.28% |
| 10-Year Change | -445.54% |
| Growth Volatility | 124.2 |
Health-Chem Corporation - Net Assets Trend (1985–2006)
This chart illustrates how Health-Chem Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Health-Chem Corporation (1985–2006)
The table below shows the annual net assets of Health-Chem Corporation from 1985 to 2006.
| Year | Net Assets | Change |
|---|---|---|
| 2006-12-31 | $-16.59 Million | -11.08% |
| 2005-12-31 | $-14.93 Million | -21.18% |
| 2004-12-31 | $-12.32 Million | +1.12% |
| 2003-12-31 | $-12.46 Million | -419.51% |
| 1997-12-31 | $3.90 Million | -45.07% |
| 1996-12-31 | $7.10 Million | -16.47% |
| 1995-12-31 | $8.50 Million | -2.30% |
| 1994-12-31 | $8.70 Million | +40.32% |
| 1993-12-31 | $6.20 Million | +29.17% |
| 1992-12-31 | $4.80 Million | +128.57% |
| 1991-12-31 | $2.10 Million | +50.00% |
| 1990-12-31 | $1.40 Million | -85.57% |
| 1989-12-31 | $9.70 Million | -9.35% |
| 1988-12-31 | $10.70 Million | +12.63% |
| 1987-12-31 | $9.50 Million | -62.30% |
| 1986-12-31 | $25.20 Million | +5.88% |
| 1985-12-31 | $23.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Health-Chem Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 307.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2006)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $179.00K | % |
| Other Components | $11.29 Million | % |
| Total Equity | $-16.59 Million | 100.00% |
Health-Chem Corporation Competitors by Market Cap
The table below lists competitors of Health-Chem Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EnviroTechnologies International Inc
PINK:ETII
|
$0.99 |
|
True North Energy Corp
PINK:TNEN
|
$0.99 |
|
OJsys Inc
PINK:OJSY
|
$0.99 |
|
QENEX Communications Inc
PINK:QNXC
|
$0.99 |
|
Black Dragon Resource Companies Inc
PINK:BDGR
|
$0.99 |
|
Infinite Networks Corporation
PINK:INNX
|
$0.99 |
|
Miracle Entertainment Inc
PINK:MEMI
|
$0.99 |
|
New World Gold Cp
PINK:NWGC
|
$0.99 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Health-Chem Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2005 to 2006, total equity changed from -14,935,000 to -16,589,000, a change of -1,654,000.
- Net loss of 1,656,000 reduced equity.
- Other factors increased equity by 2,000.
Equity Change Factors (2005 to 2006)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.66 Million | -9.98% |
| Other Changes | $2.00K | +0.01% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Health-Chem Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $3.46 | $0.00 | x |
| 1986-12-31 | $3.78 | $0.00 | x |
| 1987-12-31 | $1.33 | $0.00 | x |
| 1988-12-31 | $1.56 | $0.00 | x |
| 1989-12-31 | $0.83 | $0.00 | x |
| 1990-12-31 | $0.20 | $0.00 | x |
| 1991-12-31 | $0.25 | $0.00 | x |
| 1992-12-31 | $0.88 | $0.00 | x |
| 1993-12-31 | $0.78 | $0.00 | x |
| 1994-12-31 | $1.12 | $0.00 | x |
| 1995-12-31 | $1.13 | $0.00 | x |
| 1996-12-31 | $0.93 | $0.00 | x |
| 1997-12-31 | $0.48 | $0.00 | x |
| 2003-12-31 | $0.00 | $0.00 | x |
| 2004-12-31 | $-1.09 | $0.00 | x |
| 2005-12-31 | $-1.31 | $0.00 | x |
| 2006-12-31 | $-1.45 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Health-Chem Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.88%
- • Asset Turnover: 1.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-43.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -4.62% | -4.10% | 0.41x | 2.73x | $-3.48 Million |
| 1986 | 2.38% | 2.07% | 0.43x | 2.66x | $-1.92 Million |
| 1987 | -158.95% | -44.02% | 0.55x | 6.54x | $-16.05 Million |
| 1988 | 13.46% | 3.89% | 0.63x | 5.52x | $360.00K |
| 1989 | -18.09% | -4.02% | 0.71x | 6.31x | $-2.64 Million |
| 1990 | -592.86% | -21.73% | 0.88x | 31.00x | $-8.44 Million |
| 1991 | 23.81% | 1.35% | 0.95x | 18.62x | $290.00K |
| 1992 | 39.58% | 4.91% | 1.34x | 6.02x | $1.42 Million |
| 1993 | 43.55% | 6.01% | 1.54x | 4.71x | $2.08 Million |
| 1994 | 16.09% | 2.99% | 1.46x | 3.70x | $530.00K |
| 1995 | -3.53% | -0.65% | 1.38x | 3.96x | $-1.15 Million |
| 1996 | -18.31% | -2.73% | 1.47x | 4.56x | $-2.01 Million |
| 1997 | -84.62% | -8.75% | 1.26x | 7.67x | $-3.69 Million |
| 2003 | 0.00% | -24.99% | 1.61x | 0.00x | $-726.60K |
| 2004 | 0.00% | 0.10% | 1.23x | 0.00x | $1.25 Million |
| 2005 | 0.00% | -32.69% | 1.09x | 0.00x | $-986.50K |
| 2006 | 0.00% | -27.88% | 1.03x | 0.00x | $2.90K |
Industry Comparison
This section compares Health-Chem Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $482,684,274
- Average return on equity (ROE) among peers: -68.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Health-Chem Corporation (HCLC) | $-16.43 Million | -4.62% | N/A | $0.99 |
| Agilent Technologies Inc (A) | $4.16 Billion | 9.64% | 0.80x | $31.54 Billion |
| Amer Bio Medica (ABMC) | $2.66 Million | -28.23% | 1.26x | $3.55K |
| ADCNF (ADCNF) | $852.85 Million | 37.00% | 2.65x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $2.00 Million |
| ANGLE plc (ANPCF) | $3.82 Million | -94.09% | 0.43x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.29K |
| Avricore Health Inc (AVCRF) | $-37.20K | 0.00% | 0.00x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $3.76 Million | -397.87% | 1.13x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $52.50 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $5.08 Million |